Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836424 | 1.00 | MET (0.45) | METALKMAPK1AXLFLT3 | |
| SCHEMBL29836512 | 0.93 | MET (0.45) | METALKMAPK1AXLFLT3 | |
| SCHEMBL21591791 | 0.93 | MET (0.45) | METALKMAPK1AXLFLT3 | |
| SCHEMBL21593223 | 0.83 | MET (0.44) | METALKMAPK1AXLFLT3 | |
| SCHEMBL29836490 | 0.82 | LRRK2 (0.41) | METALKAXLROCK2ROCK1 | |
| SCHEMBL21593092 | 0.82 | LRRK2 (0.41) | METALKAXLROCK2ROCK1 | |
| SCHEMBL29836539 | 0.79 | MET (0.44) | METALKMAPK1AXLFLT3 | |
| SCHEMBL21591789 | 0.79 | MET (0.44) | METALKMAPK1AXLFLT3 | |
| SCHEMBL21593225 | 0.77 | MET (0.44) | METALKMAPK1AXLFLT3 | |
| SCHEMBL21591769 | 0.76 | MET (0.44) | METAXLMKNK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | claimed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | claimed |
| EP-3807273-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | claimed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | MET 2620/4885ALK 554/4885MAPK1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.